Skip to Main Content

Paper Details

Molecular Testing Identifies Determinants of Exceptional Response and Guides Precision Therapy in a Patient with Lethal, Treatment-emergent Neuroendocrine Prostate Cancer.
Cureus
7
2019
Author NameAffiliation
Daniel J ColemanKnight Cancer Institute, Oregon Health & Science University
George V ThomasKnight Cancer Institute, Oregon Health & Science University
Joshi J AlumkalKnight Cancer Institute, Oregon Health & Science University
  • 1 - 3

Datasets

Release 1.2